東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Preclinical modeling of multi-drug c...

Boik, John C.

FindBook

Google Book

Amazon

博客來

Preclinical modeling of multi-drug cancer therapies.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Preclinical modeling of multi-drug cancer therapies./
作者:	Boik, John C.
面頁冊數:	173 p.
附註:	Adviser: Robert A. Newman.
Contained By:	Dissertation Abstracts International68-05B.
標題:	Biology, Biostatistics. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3265289
ISBN:	9780549029427

Preclinical modeling of multi-drug cancer therapies.
Boik, John C.

Preclinical modeling of multi-drug cancer therapies. - 173 p.

Adviser: Robert A. Newman.

Thesis (Ph.D.)--The University of Texas Graduate School of Biomedical Sciences at Houston, 2007.

Anticancer drugs typically are administered in the clinic in the form of mixtures, sometimes called combinations. Only in rare cases, however, are mixtures approved as drugs. Rather, research on mixtures tends to occur after single drugs have been approved. The goal of this research project was to develop modeling approaches that would encourage rational preclinical mixture design. To this end, a series of models were developed. First, several QSAR classification models were constructed to predict the cytotoxicity, oral clearance, and acute systemic toxicity of drugs. The QSAR models were applied to a set of over 115,000 natural compounds in order to identify promising ones for testing in mixtures. Second, an improved method was developed to assess synergistic, antagonistic, and additive effects between drugs in a mixture. This method, dubbed the MixLow method, is similar to the Median-Effect method, the de facto standard for assessing drug interactions. The primary difference between the two is that the MixLow method uses a nonlinear mixed-effects model to estimate parameters of concentration-effect curves, rather than an ordinary least squares procedure. Parameter estimators produced by the MixLow method were more precise than those produced by the Median-Effect Method, and coverage of Loewe index confidence intervals was superior. Third, a model was developed to predict drug interactions based on scores obtained from virtual docking experiments. This represents a novel approach for modeling drug mixtures and was more useful for the data modeled here than competing approaches. The model was applied to cytotoxicity data for 45 mixtures, each composed of up to 10 selected drugs. One drug, doxorubicin, was a standard chemotherapy agent and the others were well-known natural compounds including curcumin, EGCG, quercetin, and rhein. Predictions of synergism/antagonism were made for all possible fixed-ratio mixtures, cytotoxicities of the 10 best-scoring mixtures were tested, and drug interactions were assessed. Predicted and observed responses were highly correlated (r2 = 0.83). Results suggested that some mixtures allowed up to an 11-fold reduction of doxorubicin concentrations without sacrificing efficacy. Taken together, the models developed in this project present a general approach to rational design of mixtures during preclinical drug development.

ISBN: 9780549029427Subjects--Topical Terms:

1018416
Biology, Biostatistics.

Preclinical modeling of multi-drug cancer therapies.
LDR:03302nam 2200277 a 45 001 943677
005 20110520
008 110520s2007 ||||||||||||||||| ||eng d
020 $a 9780549029427
035 $a (UMI)AAI3265289
035 $a AAI3265289
040 $a UMI $c UMI
100 1 $a Boik, John C. $3 1267712
245 1 0 $a Preclinical modeling of multi-drug cancer therapies.
300 $a 173 p.
500 $a Adviser: Robert A. Newman.
500 $a Source: Dissertation Abstracts International, Volume: 68-05, Section: B, page: 2971.
502 $a Thesis (Ph.D.)--The University of Texas Graduate School of Biomedical Sciences at Houston, 2007.
520 $a Anticancer drugs typically are administered in the clinic in the form of mixtures, sometimes called combinations. Only in rare cases, however, are mixtures approved as drugs. Rather, research on mixtures tends to occur after single drugs have been approved. The goal of this research project was to develop modeling approaches that would encourage rational preclinical mixture design. To this end, a series of models were developed. First, several QSAR classification models were constructed to predict the cytotoxicity, oral clearance, and acute systemic toxicity of drugs. The QSAR models were applied to a set of over 115,000 natural compounds in order to identify promising ones for testing in mixtures. Second, an improved method was developed to assess synergistic, antagonistic, and additive effects between drugs in a mixture. This method, dubbed the MixLow method, is similar to the Median-Effect method, the de facto standard for assessing drug interactions. The primary difference between the two is that the MixLow method uses a nonlinear mixed-effects model to estimate parameters of concentration-effect curves, rather than an ordinary least squares procedure. Parameter estimators produced by the MixLow method were more precise than those produced by the Median-Effect Method, and coverage of Loewe index confidence intervals was superior. Third, a model was developed to predict drug interactions based on scores obtained from virtual docking experiments. This represents a novel approach for modeling drug mixtures and was more useful for the data modeled here than competing approaches. The model was applied to cytotoxicity data for 45 mixtures, each composed of up to 10 selected drugs. One drug, doxorubicin, was a standard chemotherapy agent and the others were well-known natural compounds including curcumin, EGCG, quercetin, and rhein. Predictions of synergism/antagonism were made for all possible fixed-ratio mixtures, cytotoxicities of the 10 best-scoring mixtures were tested, and drug interactions were assessed. Predicted and observed responses were highly correlated (r2 = 0.83). Results suggested that some mixtures allowed up to an 11-fold reduction of doxorubicin concentrations without sacrificing efficacy. Taken together, the models developed in this project present a general approach to rational design of mixtures during preclinical drug development.
590 $a School code: 2034.
650 4 $a Biology, Biostatistics. $3 1018416
650 4 $a Health Sciences, Oncology. $3 1018566
690 $a 0308
690 $a 0992
710 2 $a The University of Texas Graduate School of Biomedical Sciences at Houston. $3 1019338
773 0 $t Dissertation Abstracts International $g 68-05B.
790 $a 2034
790 1 0 $a Newman, Robert A., $e advisor
791 $a Ph.D.
792 $a 2007
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3265289